company background image
ONMA logo

OncoSec Medical DB:ONMA Stock Report

Last Price

€0.085

Market Cap

€738.0k

7D

-46.3%

1Y

-99.5%

Updated

28 Jun, 2023

Data

Company Financials

OncoSec Medical Incorporated

DB:ONMA Stock Report

Market Cap: €738.0k

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

ONMA Stock Overview

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. More details

ONMA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

OncoSec Medical Incorporated Competitors

Price History & Performance

Summary of share price highs, lows and changes for OncoSec Medical
Historical stock prices
Current Share PriceUS$0.085
52 Week HighUS$17.82
52 Week LowUS$0.085
Beta2
1 Month Change-79.22%
3 Month Change-95.82%
1 Year Change-99.49%
3 Year Change-99.78%
5 Year Change-99.97%
Change since IPO-99.99%

Recent News & Updates

Recent updates

Shareholder Returns

ONMADE BiotechsDE Market
7D-46.3%6.5%1.3%
1Y-99.5%-1.9%9.0%

Return vs Industry: ONMA underperformed the German Biotechs industry which returned -23.1% over the past year.

Return vs Market: ONMA underperformed the German Market which returned 5.9% over the past year.

Price Volatility

Is ONMA's price volatile compared to industry and market?
ONMA volatility
ONMA Average Weekly Movement44.4%
Biotechs Industry Average Movement7.3%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.4%

Stable Share Price: ONMA's share price has been volatile over the past 3 months.

Volatility Over Time: ONMA's weekly volatility has decreased from 220% to 44% over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
200841n/aoncosec.com

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company’s product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma.

OncoSec Medical Incorporated Fundamentals Summary

How do OncoSec Medical's earnings and revenue compare to its market cap?
ONMA fundamental statistics
Market cap€737.99k
Earnings (TTM)-€26.94m
Revenue (TTM)n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ONMA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$29.39m
Earnings-US$29.39m

Last Reported Earnings

Jan 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-4.93
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-132.9%

How did ONMA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/06/28 00:39
End of Day Share Price 2023/06/28 00:00
Earnings2023/01/31
Annual Earnings2022/07/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

OncoSec Medical Incorporated is covered by 11 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Thomas ShraderBTIG
Raghuram SelvarajuH.C. Wainwright & Co.